Clinical trials
Phase 4 trials in Serbia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 8 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 57 |
| Terminated | 7 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 11 |
| University of Belgrade | 9 |
| Pfizer | 4 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4 |
| AstraZeneca | 3 |
| GlaxoSmithKline | 3 |
| Novo Nordisk A/S | 3 |
| Sanofi | 3 |
| Clinical Center of Vojvodina | 2 |
| Clinical Centre of Serbia | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 7 |
| Hemophilia A | 4 |
| Anemia | 3 |
| Arthritis, Rheumatoid | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colitis, Ulcerative | 3 |
| Diabetes Mellitus | 3 |
| Postoperative Pain | 3 |
| Asthma | 2 |
| Coronary Artery Disease | 2 |
Trials
Showing 51 to 74 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.